GELIFES Seminars - Kate Lambertsen
When: | Fr 03-06-2022 14:00 - 15:00 |
Where: | 5171.0415 |
Kate Lambertsen (University of Southern Denmark)
TNF-mediated neuroinflammation
Inflammation is currently considered a prime target for the development of new stroke therapies. In the acute phase of ischemic stroke, microglia are activated and then circulating immune cells invade the peri-infarct and infarct core. Resident and infiltrating cells together orchestrate the post-stroke inflammatory response, communicating with each other and the ischemic neurons, through soluble and membrane-bound signaling molecules, including cytokines. Inflammation can be both detrimental and beneficial at particular stages after a stroke. While it can contribute to expansion of the infarct, it is also responsible for infarct resolution, and influences remodeling and repair. Several pre-clinical and clinical proof-of-concept studies have suggested the effectiveness of pharmacological interventions that target inflammation post-stroke. Experimental evidence shows that targeting certain inflammatory cytokines, such as tumor necrosis factor, holds promise. However, as TNF possesses non-redundant protective and immunoregulatory functions, its neutralization or augmentation carries a risk of unwanted side effects, and clinical translation is, therefore, challenging. This talk summarizes the research performed in our lab on cell biology of the post-stroke inflammatory response and discusses pharmacological interventions targeting inflammation in the acute phase after a stroke that may be used alone or in combination with recanalization therapies.